Ranking of Cardiovascular Chinese Patent Medicines

Because cardiovascular and cerebrovascular diseases have become a disease with not only a very high incidence rate but also a very high mortality rate in modern society, with the help of modern medical technology, some drugs for treating cardiovascular and cerebrovascular diseases have also been developed, and there are also many types. However, faced with such a wide variety of drugs, many patients with cardiovascular and cerebrovascular diseases do not know how to choose. Today, we will introduce some rankings of cardiovascular and cerebrovascular Chinese patent medicines to cardiovascular and cerebrovascular patients.

Market analysis of traditional Chinese medicine for cardiovascular and cerebrovascular diseases

Cardiovascular and cerebrovascular Chinese patent medicines refer to Chinese patent medicines for the treatment of various cardiovascular and cerebrovascular diseases such as coronary heart disease, cerebral stroke, myocardial infarction and combined body weight, arrhythmia, angina pectoris and hypertension, including oral Chinese patent medicines, Chinese medicine injections and other dosage forms of products.

At present, cardiovascular and cerebrovascular diseases have become the most important diseases affecting the health level of residents. In China, about 2.6 million people die from cardiovascular and cerebrovascular diseases every year, and about 7,000 people die every day.

With the increase in the number of people suffering from cardiovascular and cerebrovascular diseases, cardiovascular and cerebrovascular drugs have become the largest category of drugs in the world's pharmaceutical market. According to IMS statistics, in 2003, cardiovascular drugs ranked first in the global pharmaceutical market, with a market share of 16.09% and a market size of US$75 billion. According to the DCCC (China Drug Stratification Consumption Model) of the Southern Pharmaceutical Economics Research Institute of SFDA, in 2003, cardiovascular and cerebrovascular drugs ranked second in the Chinese pharmaceutical market, second only to anti-infective drugs, with a market share of 14.36%.

The pathogenesis of cardiovascular and cerebrovascular diseases is relatively complex, and modern drug therapy based on molecular biology still has difficulty in effectively playing a therapeutic role in some areas. For this reason, Chinese patent medicine, as a traditional disease treatment method in my country, occupies a very important position in my country's cardiovascular and cerebrovascular drug market.

Big Market Creates Big Brand

Market size is the most important indicator to measure the characteristics of a market economy. According to the CDCC model of the Southern Medical Economics Research Institute, in 2003, the total retail scale of the domestic cardiovascular and cerebrovascular Chinese patent medicine market was approximately RMB 8.21 billion (±10%), accounting for approximately 25.41% of the overall market for cardiovascular and cerebrovascular drugs (including Chinese patent medicines and chemical drugs) and approximately 3.64% of my country's pharmaceutical market. In 2003, the brand with the largest sales volume in the cardiovascular Chinese patent medicine market was Compound Danshen Dropping Pills, with sales revenue of RMB 819 million in 2003. Based on the average market retail price, its total market retail scale is estimated to be about RMB 1.087 billion. This product is also the brand with the largest retail scale in the Chinese pharmaceutical market. Due to the large market size of cardiovascular Chinese patent medicines, it not only created the largest brand in the Chinese pharmaceutical market - Compound Danshen Drops - in terms of retail scale, but also created well-known brands with a retail scale of more than 500 million yuan, such as Tongxinluo, Buchang Naoxintong, Di'ao Xinxuekang, Suxiao Jiuxin Pills, Shuxuening, Mailuoning and Zhenju Antihypertensive Tablets.

Most Chinese patent medicines for cardiovascular and cerebrovascular diseases are used for chronic diseases and need to be taken for a long time. It is a more convenient option for consumers to choose to purchase such medicines in the retail market. However, research results show that the hospital market is still the dominant market for Chinese patent medicines for cardiovascular and cerebrovascular diseases, accounting for 78.3% of the total market, while the retail market only accounts for 21.7% of the share. The reason why the hospital market is dominant is that middle-aged and elderly patients, especially those in cities, have a higher compliance with doctors and still choose to go to the hospital mainly for medical treatment and drug purchase.

Brand dispersion and product concentration

According to relevant statistics, the sales of traditional Chinese medicines for cardiovascular diseases in 2003 increased by 23.07% compared with 2002, and the annual growth rate in 2004 is expected to be 21.62%. From 1999 to 2003, the average growth rate of the cardiovascular and cerebrovascular Chinese patent medicine market was about 23.75%. In the past five years, the average growth rate of sales revenue of Compound Danshen Drops was 34.66%, that of Quick-acting Heart-saving Pills was 22.99%, that of Tongxinluo was 45.56%, and that of Buchang Naoxintong was about 19.20%. Only the market of Diao Xinxuekang showed negative growth. Judging from the growth rate of major brands of cardiovascular and cerebrovascular Chinese patent medicines, due to the rapid growth of market demand (overall scale), major products are in an upward stage of synchronous growth, so there has not yet been fierce alternative competition among products.

In 2003, the cumulative market share of the top four brands in the cardiovascular and cerebrovascular Chinese patent medicine market was 47.61%. Judging from the absolute concentration of the overall cardiovascular and cerebrovascular Chinese patent medicine market, the cardiovascular and cerebrovascular Chinese patent medicine market is still in a relatively fragmented stage of free competition. The reason why the overall market is relatively fragmented is that, on the one hand, due to the large range of therapeutic functions of cardiovascular and cerebrovascular traditional Chinese medicines (such as the "heart and brain treatment" defined by Buchang Naoxintong Capsules and the "network disease theory" based on Tongxinluo Capsules), the direct competition level of products has expanded to cardiovascular and cerebrovascular medications, resulting in the market scope of cardiovascular and cerebrovascular traditional Chinese medicines being too large; on the other hand, it also reflects the lack of absolute competitive differences between cardiovascular and cerebrovascular traditional Chinese medicine products. While the overall market brand concentration is relatively dispersed, the market concentration of cardiovascular Chinese patent medicines is very high in specific product areas. In the market of compound danshen tablets, the cumulative market share of the top four products is 73.5%, among which the market share of compound danshen tablets produced by Baiyunshan Chinese Medicine Factory is as high as 43.83%; in the market of ginkgo oral preparations, the cumulative market share of the top four products is 71.25%; in the market of ginkgo injection, the cumulative market share of the top four products is as high as 91.45%. Therefore, from the perspective of product competition, the cardiovascular Chinese patent medicine market is still in a stage of concentrated competition dominated by brands, and the main market is still concentrated in the hands of a few brands.